Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $17.2857.

A number of equities research analysts have weighed in on ATEC shares. HC Wainwright reaffirmed a “buy” rating and set a $24.00 target price on shares of Alphatec in a research report on Thursday, May 7th. Canaccord Genuity Group dropped their price target on Alphatec from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Lake Street Capital restated a “buy” rating and set a $15.00 price target on shares of Alphatec in a research note on Wednesday, May 6th. Stephens initiated coverage on Alphatec in a report on Thursday. They issued an “overweight” rating and a $15.00 price objective for the company. Finally, Needham & Company LLC lowered their price objective on shares of Alphatec from $25.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th.

Insider Activity at Alphatec

In other news, Director Karen K. Mcginnis sold 6,050 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $8.01, for a total value of $48,460.50. Following the completion of the sale, the director owned 94,671 shares in the company, valued at approximately $758,314.71. The trade was a 6.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 13.48% of the company’s stock.

Hedge Funds Weigh In On Alphatec

Several institutional investors have recently bought and sold shares of ATEC. Handelsbanken Fonder AB purchased a new stake in Alphatec during the second quarter worth $427,000. Redhawk Wealth Advisors Inc. raised its position in shares of Alphatec by 87.8% in the 2nd quarter. Redhawk Wealth Advisors Inc. now owns 19,412 shares of the medical technology company’s stock worth $168,000 after acquiring an additional 9,077 shares in the last quarter. Atlas Brown Inc. bought a new position in shares of Alphatec in the 2nd quarter worth $111,000. Valeo Financial Advisors LLC lifted its stake in shares of Alphatec by 7.2% during the 2nd quarter. Valeo Financial Advisors LLC now owns 44,363 shares of the medical technology company’s stock worth $384,000 after purchasing an additional 2,967 shares during the last quarter. Finally, Western Wealth Management LLC lifted its stake in shares of Alphatec by 20.9% during the 1st quarter. Western Wealth Management LLC now owns 103,909 shares of the medical technology company’s stock worth $1,131,000 after purchasing an additional 17,928 shares during the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $8.26 on Monday. Alphatec has a 52-week low of $6.82 and a 52-week high of $23.29. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -10.07 and a beta of 0.85. The stock has a 50 day moving average price of $8.50 and a 200 day moving average price of $11.33. The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.12 and a current ratio of 1.90.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.